Medical Condition News

RSS
HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study

HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Finnish study finds significant regional differences in endoscopic sinus surgery

Finnish study finds significant regional differences in endoscopic sinus surgery

High diet quality associated with lower risk of death in colorectal cancer patients

High diet quality associated with lower risk of death in colorectal cancer patients

Increased cardiorespiratory fitness associated with reduced long-term mortality

Increased cardiorespiratory fitness associated with reduced long-term mortality

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

IU researchers receive $1.55 million from NIH to improve chronic-disease management

IU researchers receive $1.55 million from NIH to improve chronic-disease management

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.